Personal information

United States

Activities

Employment (1)

Pfizer: Cambridge, MA, US

2020-01-04 to present | Postdoctoral Fellow (Internal Medicine)
Employment
Source: Self-asserted source
Stephen E Flaherty III

Education and qualifications (2)

Columbia University: New York, NY, US

2015-08-18 to 2020-01-01 | PhD (Biomedical Sciences)
Education
Source: Self-asserted source
Stephen E Flaherty III

Boston College: Chestnut Hill, MA, US

2008-08-11 to 2012-05-21 | BS (Biochemistry)
Education
Source: Self-asserted source
Stephen E Flaherty III

Works (4)

Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity

Nature Communications
2023-07-04 | Journal article | Author
Part of ISSN: 2041-1723
Contributors: Stephen E Flaherty III; Olivier Bezy; Wei Zheng; Dong Yan; Xiangping Li; Srinath Jagarlapudi; Bina Albuquerque; Ryan M. Esquejo; Matthew Peloquin; Meriem Semache et al.
Source: Self-asserted source
Stephen E Flaherty III

Conditional deletion of melanin-concentrating hormone receptor 1 from GABAergic neurons increases locomotor activity.

Molecular metabolism
2019-08-28 | Journal article
Contributors: Stephen E Flaherty III
Source: Self-asserted source
Stephen E Flaherty III

A lipase-independent pathway of lipid release and immune modulation by adipocytes.

Science (New York, N.Y.)
2019-03-01 | Journal article
Contributors: Stephen E Flaherty III
Source: Self-asserted source
Stephen E Flaherty III

Melanin-concentrating hormone is necessary for olanzapine-inhibited locomotor activity in male mice.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
2015-06-03 | Journal article
Contributors: Stephen E Flaherty III
Source: Self-asserted source
Stephen E Flaherty III